Novartis Investigative Site

Esplugues, Barcelona 08950

5 studies enrolling now · 9 studies all time

What they study most

B-Cell Acute Lymphoblastic Leukemia, Chronic Spontaneous Urticaria, Familial Hypercholesterolemia - Heterozygous, Food Allergy, Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program, Lymphatic Malformations, PIK3CA-related Overgrowth Spectrum (PROS), Still´s Disease

Studies at this site

• Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. — Recruiting now
• A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease — Recruiting now
• EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) — Recruiting now
• Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia — Recruiting now
• CAR-T Long Term Follow Up (LTFU) Study — Recruiting now
• 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up — Running, not enrolling
• Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients — Running, not enrolling
• Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum — Running, not enrolling
• Long-term Extension Study of Ligelizumab in Food Allergy — Stopped early